In an oral presentation today,

Pliant Therapeutics· @PliantRX · X·2026-04-19 03:26· 2026-04-19评分60

正文 · 原文

In an oral presentation today,
@UTMDAnderson
's Dr. Timothy Yap presented updated results from our Phase 1 trial of PLN-101095 in patients with ICI-refractory solid tumors as part of the
@AACR
2026 Annual Meeting. Review the data and presentation
https://
lnkd.in/gCvrb5fQ #AACR26

热度 0 · 0 赞 · 0 回复 · 0 转发

会议摘要

CT002NCT06270706按代号 PLN-101095 对上

First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Timothy A. Yap, Andrae Vandross, Jenny Amaya-Amaya, Chris N. Barnes, Shuguang Ma, Martin Decaris, Keithryn Nicolas, Alexander Spira, Jacqueline Brown, Patricia LoRusso, Manish R. Sharma

读摘要原文 →

来源：Pliant Therapeutics · x.com